Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Biodexa Pharmaceuticals (NASDAQ: BDRX)

Last close As at 21/11/2024

0.99

▲ −0.03 (−2.94%)

Market capitalisation

5m

Edison Investment Research is terminating coverage on Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Update

Biodexa Pharmaceuticals — In a period of transition

Healthcare | Update

Biodexa Pharmaceuticals — Foray into T1D expands business scope

Healthcare | Flash note

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Healthcare | Flash note

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline
Midatech Pharma_resized
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (16.1) (22.7) (85.2)
Relative (19.6) (26.6) (88.2)
52 week high/low US$8.0/US$0.7

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2022A 0.7 (8.6) (8.5) (6.30) N/A N/A
2023A 0.4 (7.7) (7.5) (5.30) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Midatech Pharma_resized

Update

Healthcare

Biodexa Pharmaceuticals — Foray into T1D expands business scope
Midatech Pharma_resized

Flash note

Healthcare

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Healthcare

Update

Biodexa Pharmaceuticals — In a period of transition
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free